Prognostic Significance of p53 Status in Non-Small Cell Lung Cancer in Correlation with Postoperative Adjuvant Therapy

Abstract

Background and Objective: Significant factors in the prognosis of p53 status in non-small cell lung cancer (NSCLC) remain controversial; some clinical studies have documented that p53 abnormality is a significant factor in predicting poor prognosis, and others failed. In the present study, we examined whether or not adjuvant therapy may influence the prognostic significance. Methods: 217 patients with pathologic stage I disease were reviewed. As postoperative adjuvant therapy, UFT, an oral 5-fluorouracil derivative, was administered to 73 patients; p53 status was determined immunohistochemically. Results: The 5-year survival rate for tumor with aberrant p53 expression was 66.4 % - significantly lower than that for tumor without aberrant p53 expression (79.7 %, p = 0.023). The prognostic significance of p53 status was enhanced in patients who received UFT; 5-year survival rates for tumor with and without aberrant p53 expression were 68.8 and 94.7 %, respectively (p = 0.002). In patients who did not receive UFT, the difference did not reach statistical significance (5-year survival rates: 65.5 and 71.5 %, respectively; p = 0.267). Conclusions: This study demonstrates that postoperative survival is improved by UFT administration in patients with normal p53 function, but not in those without normal p53 function.

p53 - non-small cell lung cancer - adjuvant therapy

References

• 1 Mountain C F. Revisions in the international system for staging lung cancer.  Chest. 1997;  116 1710-1717
• 2 Ihde D, Ball D, Arriagada R. et al . Postoperative adjuvant theraphy for non-small cell lung cancer: a consensus report.  Lung Cancer. 1994;  11s 15-17
• 3 Wada H, Hitomi S, Teramatsu T. West Japan Study Group for Lung Cancer Surgery . Adjuvant chemotherapy after complete resection in non-small-cell lung cancer.  J Clin Oncol. 1996;  14 1048-1054
• 4 Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized chlinical trial. West Japan Study Group for lung cancer surgery (WJSG).  Eur J Cardiothorac Surg. 1999;  15 438-443
• 5 Tanaka F, Otake Y, Yanagihara K. et al . Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.  Br J Cancer. 2001;  84 263-269
• 6 Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.  Gann (Jpn J Cancer Res). 1978;  69 763-772
• 7 Vogelstein B, Kinzler K W. p53 funktion and dysfunction.  Cell. 1992;  70 523-526
• 8 Takahashi T, Nau M M, Chiba I. et al . p53: a frequent target for genetic abnormalities in lung cancer.  Science. 1989;  246 491-494
• 9 Chiba I, Takahashi T, Nau M M. et al . Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer.  Cancer Res. 1992;  52 1695-1698
• 10 Nigro M J, Baker S J, Preisinger A C. et al . Mutations in the p53 gene occur in diverse human tumor types.  Nature. 1992;  342 705-708
• 11 Quinlan D C, Davidson A G, Summers C L, Warden H E, Doshi H M. Accumulation of p53 protein correlates with poor prognosis in human lung cancer.  Cancer Res. 1992;  52 4828-4831
• 12 Morkve O, Halvorsen O J, Skjaerven R. et al . Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.  Anticancer Res. 1993;  13 571-578
• 13 Harpole D H, Herndon J E, Wolfe G W, Iglehart J D, Marks J R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression.  Cancer Res. 1995;  55 55-56
• 14 Ebina M, Steinberg S M, Mulshine J L, Linnoila R I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.  Cancer Res. 1994;  54 2496-2503
• 15 Mitsudomi T, Oyama T, Kusano T. et al . Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer.  J Natl Cancer Inst. 1993;  85 2018-2023
• 16 McLaren R, Kuzu L, Dunnil M. et al . The relationship of p53 immunostaining to survival in carcinoma of the lung.  Br J Cancer. 1992;  66 735-738
• 17 Passlick B, Izbicki J R, Riethmuller G. p53 in non-small cell lung cancer.  J Natl Cancer Inst. 1994;  86 801-802
• 18 American Society of Clinical Oncology . ASCO special article: Clinical practical guidelines for the treatment of unresectable non-small cell lung cancer.  J Clin Oncol. 1997;  15 2996-3018
• 19 Tanaka F, Kawano Y, Li M. et al . Prognostic significance of apoptotic index in completely resected non-small cell lung cancer.  J Clin Oncol. 1999;  17 2728-2736